∗Department of Intensive Care, Austin Hospital, Heidelberg, Australia
†Department of Critical Care, University of Melbourne, Melbourne, Australia
‡School of Medicine, University of Melbourne, Melbourne, Australia
§Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia
∥Department of Intensive Care, The Royal Melbourne Hospital, Parkville, Australia
¶Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia
#Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil
∗∗Data Analytics Research and Evaluation Centre, Austin Hospital, Melbourne, Australia
Received 11 Jan 2023; first review completed 31 Jan 2023; accepted in final form 21 Feb 2023
Address reprint requests to Rinaldo Bellomo, Intensive Care Unit, Austin Hospital, 145 Studley Rd, Heidelberg VIC. E-mail: [email protected]
The authors report no conflict of interest.
Assistance with study conduct was provided by the intensive care unit research team at Austin Health (Glenn Eastwood, Helen Young, Leah Peck).
Angiotensin 2 was provided by La Jolla Pharmaceuticals (La Jolla, CA) without cost for compassionate use during the first COVID-19 wave, with surplus vials provided to the Austin Health Department of Intensive Care.
Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.shockjournal.com).